Absci Corporation (ABSI) Discusses ABS-201 Program and Clinical Approach for Androgenetic Alopecia Transcript
Summarize this article with:
SA Transcripts157.31K FollowersFollow5ShareSaveComment(1)Play Earnings CallPlay Earnings Call Absci Corporation (ABSI) Discusses ABS-201 Program and Clinical Approach for Androgenetic Alopecia December 11, 2025 10:00 AM EST Company Participants Sean McClain - Founder, CEO, President & DirectorAnthony RossiAndreas Busch - Chief Innovation Officer & Member of Scientific Advisory BoardAmer-Denis AkkadRodney SinclairDavid GoldbergZachariah Jonasson - Chief Business Officer & CFO Conference Call Participants Ralf PausMike JafarVamil Divan - Guggenheim Securities, LLC, Research DivisionJacqueline Kisa - TD Cowen, Research DivisionGil Blum - Needham & Company, LLC, Research DivisionLut Ming Cheng - JPMorgan Chase & Co, Research DivisionDebanjana Chatterjee - JonesTrading Institutional Services, LLC, Research DivisionMorgan Gryga - Morgan Stanley, Research DivisionCharles Wallace - H.C. Wainwright & Co, LLC, Research DivisionAnna Li - Truist Securities, Inc., Research Division Presentation Sean McClainFounder, CEO, President & Director Good morning, everyone. Thank you for joining our deep dive today into ABS-201. At Absci, our mission is to use generative AI to create better biologics for patients who don't have good enough options today. We talk a lot about our platform, our lab-in-the-loop, and our ability to create better biologics faster. But today isn't just about the platform in the abstract, today is about the results. ABS-201, which we believe could be a paradigm-changing therapeutic for androgenic alopecia. Now historically, the biopharma industry has dismissed hair loss as just cosmetic. But when you speak to patients, you realize that characterization is deeply flawed. For tens of millions of people, both men and women, this is not about vanity. It's about identity. It's about mental health and the profound loss of confidence that impacts their daily lives. Despite this massive unmet medical need, the standard of care has remained stagnant for decades, we're relying on old mechanisms that often come with difficult trade-offs. This is why we're so excited about ABS-201, by leveraging our AI drug creation platform, we have Recommended For You